Form 4 for BBNX Beta Bionics, Inc.
Accepted 2026-06-25 16:34:10 ET · period of report 2026-06-24 · accession 0002048497-26-000009 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-06-25 16:34 | 2026-06-24 | BBNX | Hopman Mark | Chief Commercial Off | S - Sale | $15.01 | -1,258 | 129.4K | -1.0% | -$18.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-24 | S | D | 1,258 | $15.01 | 129,354 | D | — | — | (F1) Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 13, 2025. (F2) The weighted average sale price for the transaction reported was $15.0083 and the range of prices were between $15.00 and $15.015. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |